Every 8-K that VISKASE HOLDINGS INC (ENZN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ENZN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENZN filings page.
Viskase Holdings, Inc. adopted a Section 382 tax benefits preservation plan and related rights agreement to help protect the value of its net operating loss carryforwards (NOLs). The Board declared a dividend of one purchase right for each share of common stock outstanding to holders of record on May 15, 2026.
Each right allows, under certain conditions, the purchase of one one-thousandth of a share of Series A-2 Junior Participating Preferred Stock at $30.00 per right. The plan is triggered if a holder’s beneficial ownership reaches 4.9% or more of the common stock (subject to grandfathering and exemptions), which is designed to reduce the risk of an “ownership change” that could limit use of NOLs. The rights plan generally expires on May 4, 2029, unless earlier redeemed, exchanged, terminated, or not approved by stockholders by May 4, 2027.
Viskase Holdings, Inc. announced that its wholly owned subsidiary Viskase Companies, LLC entered into a Seventh Amendment to its Credit Agreement, extending the debt maturity date from August 13, 2026 to August 13, 2027.
The amendment increases the Applicable Rate by 1.0 percentage point on revolving loans, term loans and letters of credit, adjusts the definition of Consolidated EBITDA for certain restructuring and transaction costs, and permits asset dispositions at the Osceola Facility and Chicago Property. The amended facility continues to include customary covenants, is guaranteed by material restricted subsidiaries (other than Brazilian subsidiaries), and is secured by substantially all assets other than real property.
Viskase Holdings, Inc., formerly Enzon Pharmaceuticals, Inc., completed its merger with Viskase Companies, Inc. and subsequently changed its corporate name. Following this transaction, the Audit Committee appointed Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with unanimous Board ratification, subject to completion of client acceptance procedures.
Grant Thornton previously served as Viskase’s auditor before the merger. As a result of the change, EisnerAmper LLP, Enzon’s prior auditor, was dismissed. EisnerAmper’s reports on the company’s 2024 and 2025 financial statements were unqualified, and the company reports no disagreements or reportable events with EisnerAmper during that period. The company also states it did not consult Grant Thornton on accounting or auditing matters before the appointment.
Viskase Holdings, Inc. has promoted long-time finance executive Michael Blecic to Chief Financial Officer, effective April 10, 2026. Blecic, age 57, has worked at the company’s subsidiary since 1995 and has served as Vice President, Chief Accounting Officer and Treasurer since February 2013, roles he will retain.
The interim Chief Financial Officer engagement with Mackenzie Stender through Silverman Consulting, Inc. ended as of the same date. Viskase also appointed Joseph D. King as Executive Vice President while he continues as Senior Vice President, General Counsel and Secretary. Neither Blecic nor King will receive additional compensation beyond normal annual merit increases for these new titles.
Viskase Holdings, Inc., formerly Enzon Pharmaceuticals, completed its all-stock merger with Viskase Companies, Inc., making Viskase a wholly owned subsidiary that has been converted into Viskase Companies, LLC. The combined company will focus on Viskase’s meat and poultry casing business.
Enzon stockholders immediately before the merger own approximately 45% of the combined company’s common stock, while former Viskase stockholders own about 55%. Each share of Viskase common stock was converted into the right to receive 0.049118 shares of company common stock.
Before closing, 39,277 shares of Series C Preferred Stock held by Icahn Enterprises affiliates were exchanged into 5,658,396 common shares. The company changed its name to Viskase Holdings, Inc., eliminated its Series A-1 Junior Participating Preferred Stock designation, and its common stock is trading on the OTCQB under temporary symbol ENZND for 20 trading days.
Enzon Pharmaceuticals, Inc. reported that it has completed the exchange offer relating to its Series C Non-Convertible Redeemable Preferred Stock. The company disclosed this by issuing a press release, which is included as an exhibit to the report and incorporated by reference.
The information and attached press release are being furnished rather than filed, meaning they are not subject to certain liability provisions under the Exchange Act or automatically incorporated into other securities law filings unless specifically referenced.
Enzon Pharmaceuticals, Inc. approved an Eleventh Amendment to its Section 382 Rights Agreement, moving the rights’ Final Expiration Date to noon, New York City time, on March 26, 2026, with no other changes to the agreement.
The company also implemented a previously approved 1-for-100 reverse stock split, effective at 4:30 p.m. Eastern on March 24, 2026. Every 100 shares of common stock are being combined into 1 share, with the par value unchanged and fractional holdings settled in cash. Enzon’s common stock is expected to begin trading on a split-adjusted basis on the OTCQB on March 25, 2026 under the temporary symbol “ENZND” for 20 trading days. The reverse split was completed to make authorized shares available for the anticipated merger with Viskase Companies, Inc. and related common stock issuances in an outstanding exchange offer.
Enzon Pharmaceuticals, Inc. announced that it has extended the expiration date of its exchange offer for shares of its Series C Non-Convertible Redeemable Preferred Stock to 5:00 p.m. Eastern time on March 24, 2026. The offer lets holders swap preferred shares for Enzon common stock.
The exchange offer is part of a broader set of proposed transactions between Enzon and Viskase Companies, Inc., which are described in a previously filed Form S-4 registration statement containing a prospectus, consent solicitation statement and offer to exchange for the combined company.
Enzon Pharmaceuticals, Inc. reported that it entered into a Tenth Amendment to its Section 382 Rights Agreement, extending the Final Expiration Date of the rights from noon, New York City time, on March 18, 2026 to noon, New York City time, on March 24, 2026.
Management states that this new March 24, 2026 expiration is believed to be in the best interests of the company and its stockholders. Apart from the new Final Expiration Date, all other terms of the Rights Agreement remain unchanged.
Enzon Pharmaceuticals reported that it has extended the expiration date of its exchange offer to holders of Series C Non-Convertible Redeemable Preferred Stock, who are being offered Enzon common stock in exchange for their preferred shares. The offer now expires at 5:00 p.m. Eastern time on March 19, 2026, unless further extended.
This exchange offer is part of a broader proposed transaction between Enzon and Viskase Companies, Inc., for which Enzon has filed a Form S-4 registration statement containing a combined prospectus, consent solicitation statement and offer to exchange. The filing also reiterates extensive forward-looking risk factors that could affect completion and outcomes of the proposed merger and the combined company.
Enzon Pharmaceuticals, Inc. entered into a Ninth Amendment to its Section 382 Rights Agreement, moving the rights’ Final Expiration Date from noon, New York City time, on March 11, 2026, to noon, New York City time, on March 18, 2026. Management states this extension is in the best interests of the company and its stockholders, and all other terms of the rights plan remain unchanged. The company also announced that its exchange offer to swap Series C Non-Convertible Redeemable Preferred Stock for Enzon common stock has been extended to 5:00 p.m. Eastern time on March 16, 2026, unless further extended. The filing also reminds investors that Enzon has filed a Form S-4 registration statement for its proposed merger with Viskase Companies, Inc., which contains detailed information about the combined company.
Enzon Pharmaceuticals, Inc. announced that it has extended the expiration date of its exchange offer to holders of its Series C Non-Convertible Redeemable Preferred Stock, who may exchange those shares for Enzon common stock. The offer now expires one minute after 11:59 p.m., Eastern time, on March 11, 2026, unless further extended.
The update sits alongside disclosures about Enzon’s proposed merger with Viskase Companies, Inc. and references a previously filed Form S-4 registration statement that includes a prospectus, consent solicitation statement and offer to exchange, as well as detailed risk factors and forward-looking statement warnings for the combined company.
Enzon Pharmaceuticals, Inc. entered into an Eighth Amendment to its Section 382 Rights Agreement, moving the Final Expiration Date for the rights from March 2, 2026 to noon, New York City time, on March 11, 2026. No other terms of the rights plan were changed.
Enzon also extended the expiration date of its exchange offer to swap Series C Non-Convertible Redeemable Preferred Stock for Enzon common stock. The offer now expires one minute after 11:59 p.m., Eastern time, on March 9, 2026, unless extended. The filing also references an S-4 registration statement for the proposed merger with Viskase Companies, Inc.
Enzon Pharmaceuticals, Inc. reported that its stockholders have approved key proposals related to its planned merger with Viskase and a reverse stock split through a consent solicitation.
The Reverse Stock Split Proposal was approved by holders of 40,993,338 shares of Enzon common stock, representing 55.2% of issued and outstanding shares. The Merger Proposal was approved by holders of 42,350,448 shares, or 57.1% of issued and outstanding shares, based on 74,214,603 shares outstanding as of the January 29, 2026 record date.
A sufficient number of consents were received by 8:00 a.m. Eastern Time on February 11, 2026, at which point the consent period and revocation rights ended. Closing of the merger transactions remains subject to satisfaction or waiver of the remaining conditions in the Merger Agreement, as described in the Enzon–Viskase registration statement on Form S-4.
Enzon Pharmaceuticals, Inc. has amended its Section 382 Rights Agreement again, entering into a Seventh Amendment on January 30, 2026. This amendment changes the Final Expiration Date of the rights from the close of business on January 31, 2026 to noon New York City time on March 2, 2026.
The company states that management believes setting the new March 2, 2026 expiration is in the best interests of the company and its stockholders. Aside from this new expiration timing, all other terms of the Rights Agreement and prior amendments remain unchanged.
Enzon Pharmaceuticals, Inc. disclosed that it entered into a Sixth Amendment to its Section 382 Rights Agreement with Continental Stock Transfer & Trust Company. This amendment changes only the Final Expiration Date of the rights issued under the agreement, moving it from the close of business on December 31, 2025 to the close of business on January 31, 2026.
The company notes that, apart from this new expiration date, all other terms of the Rights Agreement remain unchanged. Management states that adopting a Final Expiration Date of January 31, 2026 is believed to be in the best interests of the company and its stockholders. The amendment is filed as an exhibit and incorporated by reference along with the prior amendments to the Rights Agreement.
Enzon Pharmaceuticals amended its merger agreement with Viskase Companies and the related support agreement with Icahn Enterprises Holdings (IEH). The updates reflect recent developments at Viskase and expected near‑term operations. A Special Committee of independent directors at both companies recommended the amendments, and each board approved them.
Under the amended IEH support agreement, IEH will deliver written consents for all Enzon common shares it holds to approve the merger and a charter amendment. IEH will also exchange all Series C Preferred Stock into Enzon common stock before closing, based on the full liquidation preference and the 20‑Day VWAP.
Enzon plans to file a Form S‑4 including a consent solicitation statement to seek shareholder approval for the amended merger terms, a name change to Viskase Holdings, Inc., and a Reverse Stock Split. The combined company’s board is anticipated to include Jordan Bleznick, Randolph C. Read, and additional directors designated by Viskase. Enzon believes its net operating losses and other tax benefits will be maintained and available to the combined company following the merger.
Enzon Pharmaceuticals, Inc. has amended its Section 382 Rights Agreement again to adjust the length of its shareholder rights plan. On September 30, 2025, the company entered into a Fifth Amendment that changes the Final Expiration Date of the rights from the close of business on September 30, 2025 to the close of business on December 31, 2025. This plan is designed under Section 382 of the tax code, which typically relates to preserving tax attributes such as net operating losses by discouraging certain changes in ownership.
The company notes that, aside from extending the Final Expiration Date, the terms of the Rights Agreement remain unchanged. Management states that it believes setting a Final Expiration Date of December 31, 2025 is in the best interests of the company and its stockholders. Prior amendments had repeatedly adjusted the expiration date over the last several years, and all versions of the agreement and amendments are incorporated by reference as exhibits.